(702) 683-8946

Monday - Friday 9am to 5pm

triangle
ad1

http://crweworld.com/assets/images/ad/content-delivery-solution.jpg

Our content delivery solution through CRWE WORLD, CRWE Press Release and CRWE Tubegives corporations and businesses a vehicle to expand their exposure

Content Delivery Solution (Learn More)

ad3

https://crweworld.com/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

https://crweworld.com/assets/images/ad/submit_a_press_release.jpg

Submit Your Press Release/News to the CRWE WORLD Network for $14.95! Increase Visibility, Boost Your Business

www.CRWEPressRelease.com






Momentum Building: Delcath Systems Spikes on HEPZATO KIT's FDA Nod

  • August 15th, 2023
  • 227 views

Shares of Delcath Systems, Inc. (Nasdaq: DCTH) surged over 50% following the announcement of FDA approval for HEPZATO KIT (melphalan/Hepatic Delivery System). 

This liver-directed therapy is now authorized for adult patients battling metastatic uveal melanoma (mUM), specifically those with unresectable hepatic metastases affecting less than 50% of the liver and limited extrahepatic disease. 

This approval addresses a rare and aggressive cancer with high liver involvement, making it a significant advancement in treatment options and the company plans to make the commercial product available in the fourth quarter. 

$DCTH was trading at $5.35 in pre-market, reflecting a substantial increase of $2.23 (+71.47%)

 

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)

Tags

Social Shares

Post Your Comments

Want To Find Some News?

Recent Posts

News By Industries

Tags


Warning: Undefined array key "hashid" in /var/www/html/subs/visit_counter.php on line 13